Roche asks court to stop launch of Novartis’ MabThera biosimilar

Healthcare 2018-05-15 10:45 pm By Miklos Bolza | Sydney

Please login to bookmark

Drug giant F. Hoffman-La Roche asked the Federal Court Tuesday for an order barring the release of a generic version of its blockbuster cancer drug MabThera by a unit of Swiss rival Novartis, which it claims could lead to “tens of millions of dollars” in losses.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au